-
Immunocore Tebentafusp Shows Survival Benefit In Untreated Eye Cancer Patients
Thursday, September 23, 2021 - 7:36am | 207Read More...Immunocore Holdings Plc (NASDAQ: IMCR) announced that data from a Phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator's choice in first-line metastatic uveal melanoma (mUM) had been published in The New England Journal of Medicine. The paper concluded...
-
Immunocore's Eye Cancer Candidate Under Priority Review In US, Europe
Tuesday, August 24, 2021 - 9:23am | 307Read More...The U.S. and European Union regulators have accepted for review Immunocore Holdings Plc's (NASDAQ: IMCR) marketing applications seeking approval for tebentafusp for uveal melanoma (eye cancer). Related: Newly Listed Immunocore's Tebentafusp Receives Breakthrough Therapy...
-
Delcath Systems' Hepzato Achieves 44% Best Overall Response Compared to Best Alternative Care in Eye Cancer
Monday, June 7, 2021 - 12:21pm | 349Read More...Delcath Systems Inc (NASDAQ: DCTH) has announced positive preliminary efficacy results from its FOCUS Phase 3 trial evaluating Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma. Data were presented...
-
Delcath Stock Moves Higher After Hepzato Achieves ORR Of 29.2% Beating Prespecified Threshold In Eye Cancer Study
Wednesday, March 31, 2021 - 8:06am | 267Read More...Delcath Systems Inc (NASDAQ: DCTH) has announced top-line preliminary results from the Phase 3 FOCUS trial of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma. Based on the preliminary...
-
Newly Listed Immunocore's Tebentafusp Receives Breakthrough Therapy Tag For Eye Cancer
Friday, February 19, 2021 - 9:11am | 252Read More...The FDA has designated Breakthrough Therapy status to Immunocore Holdings PLC's (NASDAQ: IMCR) tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive in adult patients with unresectable or metastatic uveal melanoma (mUM), cancer of the eye involving the iris...
